ANZLG HD3/TROG 99.01 - Hodgkins Disease IFRT - HD3 - TROG Cancer Research

By w.paterson
14 August, 2021
0 Comments

An ANZLG / TROG Prospective Study of Limited Chemotherapy and Involved Field Radiotherapy for Patients With Clinical Stage I-II Hodgkin’s Disease

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Related Post

DECREASE trial into prostate cancer

8 July, 2025

Recruitment Milestone Achieved for TROG 19.06 DECREASE Trial

TRIAL UPDATE: 8 July 2025 The TROG 19.06 DECREASE

Geoff Zipper - aka Swamp - on the Kokoda Trail

26 June, 2025

Cancer Survivor to Take on Fifth Kokoda trek to Support TROG

LATEST NEWS: 26 June 2025 He may be 76

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

Latest News

Keep up to date with TROG news, subscribe to our community newsletter.

ABN: 45 132 672 292